US FDA Centers Will Report Directly To Gottlieb: 'Flattened' Structure Will Make Future Political Transitions Easier
You may also be interested in...
The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).
'You have much less time in these jobs than you think you’re going to have,' Gottlieb says.